Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data reveals notable fluctuations in the net income attributable to Merck & Co., Inc. over the five-year period from 2020 to 2024. Both reported and adjusted net income figures are closely aligned, indicating minimal adjustments between these two measures.
- Trend Analysis
-
From 2020 to 2022, there is a clear upward trajectory. Reported net income increased substantially from approximately 7.1 billion US dollars in 2020 to around 14.5 billion US dollars in 2022, representing more than a twofold growth over this period.
However, the year 2023 exhibits a dramatic dip, with reported net income plunging to 365 million US dollars. This represents an abrupt and significant decline compared to the prior year.
The financial performance rebounds strongly in 2024, with net income reaching 17.1 billion US dollars, exceeding all previous years observed. This suggests a recovery and possibly an improvement in profitability relative to the previous peak year of 2022.
- Insights
-
The tight concordance between reported and adjusted net income over all years implies that special items or one-time adjustments had minimal effect on reported profitability.
The sharp drop in 2023 could indicate a significant non-recurring event, operational challenges, or accounting reclassifications impacting that year’s results. Conversely, the strong recovery in 2024 highlights either the resolution of those adverse influences or notable business growth initiatives paying off.
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Net Profit Margin
- The net profit margin showed a significant increase from 14.72% in 2020 to a peak of 26.79% in 2021. It then decreased slightly to 24.49% in 2022 before experiencing a sharp decline to 0.61% in 2023. The margin rebounded strongly to 26.68% in 2024. The adjusted net profit margin followed the same pattern, indicating consistent underlying profitability trends once adjustments were made.
- Return on Equity (ROE)
- The reported ROE improved from 27.91% in 2020 to 34.17% in 2021, followed by a decline to 31.57% in 2022. In 2023, ROE dropped markedly to 0.97%, signaling a significant reduction in equity profitability that year. However, it recovered to its highest point of 36.96% in 2024. The adjusted ROE mirrored these movements, confirming the observed fluctuations are not due to accounting adjustments but rather reflect actual business performance.
- Return on Assets (ROA)
- The reported ROA increased steadily from 7.72% in 2020 to 12.35% in 2021 and further to 13.3% in 2022, suggesting improved asset efficiency. Yet, a pronounced drop to 0.34% occurred in 2023, indicating a significant underutilization or impairment of assets during that period. By 2024, ROA rose again to 14.62%, reaching the highest level within the timeframe. Adjusted ROA parallels the reported figures, signaling that asset returns were consistently affected by operational performance rather than accounting methods.
- Overall Insights
- Across all metrics, the year 2023 stands out as an anomaly marked by a drastic decline in profitability and asset returns. This suggests the occurrence of an extraordinary event or adverse condition that severely impacted financial performance. The subsequent recovery in 2024 demonstrates resilience and a return to strong financial health, surpassing prior performance peaks in net profit margin, ROE, and ROA. The close alignment of reported and adjusted figures indicates that these trends are reflective of fundamental business results rather than accounting adjustments.
Merck & Co. Inc., Profitability Ratios: Reported vs. Adjusted
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Net profit margin = 100 × Net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =
The financial performance over the periods presented exhibits notable fluctuations in net income and profit margins. Both reported and adjusted net income attributable to the company demonstrate a general upward trend from 2020 through 2024, with a significant dip in 2023.
- Net Income Trends
- The reported net income increases considerably from 7,067 million US dollars in 2020 to 13,049 million in 2021, marking a substantial growth. This positive trajectory continues into 2022 with an increase to 14,519 million US dollars. However, in 2023, net income experiences a steep decline to 365 million US dollars, representing a sharp anomaly within the period analyzed. Following this drop, net income recovers robustly in 2024 to 17,117 million US dollars, the highest reported in the data set.
- The adjusted net income values mirror the reported figures closely, indicating that adjustments made to the reported figures have minimal impact on the overall net income reported, except for possibly reflecting minor accounting or non-cash adjustments.
- Profit Margin Analysis
- The reported net profit margin exhibits a similar pattern to net income. It starts at 14.72% in 2020 and nearly doubles in 2021 to 26.79%, signifying much higher profitability or operational efficiency during this period. The margin slightly decreases to 24.49% in 2022 but remains high relative to 2020. The year 2023 again shows a substantial drop in profitability to 0.61%, reflecting the significant fall in reported net income that year. In 2024, the profit margin rebounds firmly to 26.68%, nearing the peak seen in 2021.
- The adjusted net profit margin follows the same path as the reported margin, reinforcing the observation that adjusted figures largely validate the reported profitability measures without significant deviation.
Overall, the data indicates a period of strong financial performance interrupted by an extraordinary downturn in 2023. The recovery in 2024 surpasses previous years' profitability and net income levels, suggesting effective corrective measures or favorable business conditions following the downturn. The close alignment of reported and adjusted results implies consistency and reliability in the company's financial reporting during the period analyzed.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =
2 Adjusted ROE = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =
The financial data reveals significant fluctuations in both reported and adjusted net income attributable to the company over the five-year period. Notably, net income experienced a marked increase from 7,067 million USD in 2020 to 13,049 million USD in 2021, and further growth to 14,519 million USD in 2022. However, a sharp decline is observed in 2023, where net income dropped abruptly to 365 million USD, followed by a strong recovery to 17,117 million USD in 2024. This volatility suggests an exceptional event or series of events impacting profitability in 2023, with a return to elevated earnings the following year.
Return on equity (ROE), both reported and adjusted, mirrors the net income trends closely, indicating consistency in equity performance measurement. The ROE rose from 27.91% in 2020 to 34.17% in 2021, followed by a slight decrease to 31.57% in 2022. Similarly, a dramatic fall is recorded in 2023 to 0.97%, corresponding with the net income collapse. The subsequent rebound to 36.96% in 2024 surpasses previous levels, suggesting an exceptionally strong return on shareholder equity in that year.
The close alignment between reported and adjusted figures across both net income and ROE metrics indicates that adjustments made do not materially alter the underlying financial performance trends. The data as a whole reflects a period of growth through 2022, a significant disruption in 2023, and a robust recovery in 2024, underscoring the importance of investigating the causes behind the 2023 anomaly to fully understand its impact on the company's financial health and operational dynamics.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =
2 Adjusted ROA = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =
The financial data presents several notable trends in profitability and return on assets over the reported periods.
- Net Income attributable to Merck & Co., Inc.
- The reported net income demonstrates significant fluctuations across the years. From 2020 to 2022, a steady increase is observed, rising from approximately 7.1 billion USD in 2020 to about 14.5 billion USD in 2022. This upward trend nearly doubles net income over two years. However, 2023 reports a sharp decline to 365 million USD, indicating a substantial drop in profitability for that year. The subsequent year, 2024, shows a strong recovery, with net income rebounding to 17.1 billion USD, exceeding all previous reported values in this set.
- Adjusted Net Income
- The adjusted net income closely mirrors the reported net income, indicating minimal adjustments affecting the net income figures. The same pattern of a steady increase from 2020 to 2022, a drastic fall in 2023, and a significant recovery in 2024 is observed.
- Return on Assets (ROA)
- The reported ROA follows the trend seen in net income. It improves from 7.72% in 2020 to a peak of 13.3% in 2022, reflecting enhanced asset efficiency and profitability during this period. In 2023, ROA plunges dramatically to 0.34%, correlating with the sharp net income decrease, showing a temporary erosion of asset profitability. The following year sees a robust recovery in ROA to 14.62%, indicating not only a restoration but an improvement in the company’s ability to generate earnings from its assets.
- Adjusted ROA
- The adjusted ROA figures are identical to the reported ROA values, suggesting that adjustments made to net income have a negligible effect on return on asset calculations in this context.
In summary, the data reveals a business cycle characterized by accelerated growth in profitability and return on assets from 2020 through 2022, a severe disruption in 2023 leading to strong declines, followed by a marked recovery and performance improvement in 2024. The close alignment of reported and adjusted figures suggests that exceptional or one-time items had limited impact on these key profitability metrics. The sharp decline in 2023 may warrant further investigation to understand underlying causes, while the subsequent recovery indicates resilience and effective management response.